Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants With Functional Constipation (FC) or Irritable Bowel Syndrome With Constipation (IBS-C)

NCT04166058 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04166058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04166058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants With Functional Constipation (FC) or Irritable Bowel Syndrome With Constipation (IBS-C)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
November 19, 2019
Completion date
June 5, 2025
Enrollment
381 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

functional constipation, irritable bowel syndrome with constipation